Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.9500 (3.42%) ($6.5600 - $6.9500) on Thu. Sep. 8, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.8% (three month average) | RSI | 49 | Latest Price | $6.9500(3.42%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) SMH(97%) IBUY(84%) IDRV(68%) IGOV(78%) SIL(68%) | Factors Impacting TGTX price | TGTX will decline at least -3.4% in a week (0% probabilities). USO(-35%) OIH(-11%) XME(-4%) TBT(-96%) UUP(-63%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.4% (StdDev 6.8%) | Hourly BBV | 1.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-9.24(-232.95%) | Resistance Level | $7.13 | 5 Day Moving Average | $6.73(3.27%) | 10 Day Moving Average | $6.84(1.61%) | 20 Day Moving Average | $7.13(-2.52%) | To recent high | -17.5% | To recent low | 86.1% | Market Cap | $880m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |